Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
| Autor: | Ariadna Balada-Bel, Nuria Viñolas, Mónica Garzón-Ibáñez, Rafael Rosell, S. Calabuig, Carlos Camps, Irene Moya-Horno, Núria Jordana-Ariza, A.K. Santos-Rodríguez, Niki Karachaliou, D. Aguiar, Daniela Morales-Espinosa, Ana Pérez-Rosado, Maria José Catalán, Maria Gonzalez-Cao, Maria-de-los-Llanos Gil, Raquel Campos, Xavier Gonzalez, Santiago Viteri-Ramirez, Beatriz García-Peláez, J.C. Monasterio, M.A. Molina-Vila, M.A. Muñoz-Quintana, Jordi Bertran-Alamillo, Margarita Majem, Alejandro Martinez-Bueno, J. Remon-Massip, Sergi Villatoro, E. Jantus, P. Lianes-Barragan, A.E. Sosa, Clara Mayo-de-las-Casas, Noemí Reguart, E. Ovalle |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Adult Male medicine.medical_specialty Pathology Lung Neoplasms medicine.medical_treatment Decision Making NSCLC Real-Time Polymerase Chain Reaction Targeted therapy 03 medical and health sciences 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung Biopsy medicine Carcinoma Humans Genetic Testing Prospective Studies Liquid biopsy Prospective cohort study Lung cancer Protein Kinase Inhibitors Genetic testing Aged medicine.diagnostic_test liquid biopsy business.industry Hematology tyrosine-kinase inhibitors (TKIs) Middle Aged Resistance mutation medicine.disease EGFR mutations respiratory tract diseases ErbB Receptors 030104 developmental biology Treatment Outcome Drug Resistance Neoplasm 030220 oncology & carcinogenesis Mutation Female business |
| Zdroj: | ANNALS OF ONCOLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Annals of Oncology r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol |
| ISSN: | 1569-8041 0923-7534 |
| Popis: | Background: In a significant percentage of advanced non-small-cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses. We prospectively analyzed if circulating-free DNA (cfDNA) purified from blood can be used as a surrogate in this setting to select patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Patients and methods: Blood samples were collected in 119 hospitals from 1138 advanced NSCLC patients at presentation (n = 1033) or at progression to EGFR-TKIs (n = 105) with no biopsy or insufficient tumor tissue. Serum and plasma were sent to a central laboratory, cfDNA purified and EGFR mutations analyzed and quantified using a real-time PCR assay. Response data from a subset of patients (n = 18) were retrospectively collected. Results: Of 1033 NSCLC patients at presentation, 1026 were assessable; with a prevalence of males and former or current smokers. Sensitizing mutations were found in the cfDNA of 113 patients (11%); with a majority of females, never smokers and exon 19 deletions. Thirty-one patients were positive only in plasma and 11 in serum alone and mutation load was higher in plasma and in cases with exon 19 deletions. More than 50% of samples had |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|